Some leading vaccine manufacturers could be exposed to litigation they've been protected from for decades if the U.S. decides to adopt a new childhood vaccine schedule resembling Denmark's, as it appears likely to do in the new year.
Why it matters: The threat of expensive lawsuits could ultimately drive vaccine makers from the U.S. market, upending access to shots like those protecting against the seasonal flu, hepatitis and meningitis.
